CD44 and neoplasm: GBMs expressing CD44 at a much higher level in the tumor periphery than in the tumor core (high P/C ratio of CD44) were refractory to Bev therapy, and patients showed much shorter survival than when their tumors expressed a low P/C ratio of CD44.